Airway MMP-12 and DNA methylation in COPD: an integrative approach
- PMID: 39794761
- PMCID: PMC11724436
- DOI: 10.1186/s12931-024-03088-3
Airway MMP-12 and DNA methylation in COPD: an integrative approach
Abstract
Background: In COPD, the balance between matrix metalloproteinases (MMPs) and their natural inhibitors [tissue inhibitors of metalloproteinases (TIMPs)] is shifted towards excessive degradation, reflected in bronchoalveolar lavage (BAL) as increased MMP concentrations. Because of their critical role in lung homeostasis, MMP activity is tightly regulated, but to what extent this regulation occurs through epigenetic mechanisms remains unknown.
Methods: To explore the interplay between MMPs, TIMPs, and DNA methylation (DNAm) we (1) analysed MMP-9, -12, and TIMP-1 concentrations in BAL fluid, and profiled DNAm in BAL cells from 18 COPD and 30 control subjects, (2) estimated protein-COPD relationships using multivariable regression, (3) identified protein quantitative trait methylation loci (pQTMs) with COPD as a potential modifier in a separate interaction model, and (4) integrated significant interactions with a previous COPD GWAS meta-analysis.
Results: COPD was associated with higher levels of BAL MMP-12 (p = 0.016) but not with MMP-9 or TIMP-1. Further examination of MMP-12 identified association with DNAm at 34 loci (pQTMs), with TGFBR2 (p = 2.25 × 10-10) and THBS4 (p = 1.11 × 10-9) among the top ten pQTM genes. The interaction model identified 66 sites where the DNAm-MMP-12 association was significantly different in COPD compared to controls. Of these, one was colocalized with SNPs previously associated with COPD.
Conclusions: Our findings indicate that airway MMP-12 may partially be regulated by epigenetic mechanisms and that this regulation is disrupted in COPD. Furthermore, integration with COPD GWAS data suggests that this dysregulation is influenced by a combination of environmental factors, disease processes, and genetics, with the latter potentially playing a lesser role.
Keywords: Bronchoscopy; Chronic obstructive pulmonary disease (COPD); DNA methylation; Extracellular matrix remodelling; Matrix metalloproteinases (MMPs); Multiomics.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Informed consent was obtained from all volunteers after verbal and written information. The Ethics Committee at Umeå University, Sweden, granted approval for the study; registration number 2011-147-31M (original study) and 2017-91-32M (additional approval for DNA methylation measurement). The study was performed in accordance with the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
References
-
- Churg A, Zhou S, Wright JL. Matrix metalloproteinases in COPD. Eur Respir J. 2011;39:197–209. - PubMed
-
- Beurden PAMS, den Hoff JWV. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005;38:73–83. - PubMed
-
- Casas-Recasens S, Cassim R, Mendoza N, Agusti A, Lodge C, Li S, et al. Epigenome-wide association studies of COPD and lung function: a systematic review. Am J Respir Crit Care Med. 2024. 10.1164/rccm.202302-0231OC. - PubMed
-
- Roach HI, Yamada N, Cheung KSC, Tilley S, Clarke NMP, Oreffo ROC, et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum. 2005;52:3110–24. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
